Direct Answer
190 SEC filers are classified under the Standard Industrial Classification code that describes the generic pharmaceuticals industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Generic pharmaceutical companies make and sell off-patent copies of branded drugs at low prices, earning small margins on large volumes. Scale, manufacturing cost and speed of launch after patent expiry determine returns. The first numbers to compare across companies here are volume and price erosion, gross margin and new launches and first-to-file exclusivities.
Key Industry Metrics
- Volume and price erosion: Units sold and the decline in price as competitors enter. Generic prices typically fall as more makers launch, so volume growth must outpace price decline.
- Gross margin: Share of sales left after manufacturing cost. Margins are thin and sensitive to price erosion, plant efficiency and the mix of products.
- New launches and first-to-file exclusivities: Products introduced and periods when a first filer sells without generic rivals. Exclusivity brings higher prices for a limited time, so these launches often contribute outsized profit.
- Manufacturing cost: Cost to produce each unit, including materials, labor and plant overhead. Low cost is the main competitive tool, so improvements directly raise margin.
- Customer concentration among wholesalers: Share of sales to the few large drug wholesalers and chains. Those buyers have strong pricing power, so losing one can affect revenue and pressure prices.
Primary Macro Drivers
- Patent expirations: When branded drugs lose exclusivity, copies can launch, so the expiry calendar sets which products offer volume and who gets early exclusivity.
- Regulatory approvals: Approval of each application allows a launch, so regulator timing and backlog set when new products start contributing.
- Buyer consolidation: Wholesalers and buying groups are few and large, so consolidation gives them more power over price and lowers price per unit.
- Raw material and manufacturing cost: Ingredients and plant costs set gross margin on products with thin pricing, so input costs and efficiency matter.
Major Risks
- Price erosion: Competition among makers pushes prices down on many older products, so price erosion offsets volume; watch volume and price erosion.
- Customer concentration: A few wholesalers account for much of sales, so a contract change or loss moves results; watch customer concentration disclosures.
- Quality and inspection issues: Failing an inspection can halt shipments, lead to recalls and delay approvals; watch inspection findings and warning letters.
- Litigation: Suits over pricing or patents can bring damages and settlements; watch legal proceedings and reserves.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Mature |
| Geographic Importance | Global |
Generic Pharmaceuticals Filers in the SEC Record
190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| Eli Lilly & Co | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| Pfizer Inc | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| Abbvie Inc. | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| Bristol Myers Squibb Co | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| Abbott Laboratories | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| Viatris Inc | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 |
The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Generic Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Genomics & Sequencing
- Gene Therapy
- Health Care Analytics
- Gene Editing
- Health Care Equipment & Supplies
- Fertility Services
- Health Care Payments Technology
- European Pharmaceuticals
Put it to work
Frequently Asked Questions
What are the main KPIs for the Generic Pharmaceuticals industry?
Key performance indicators for the Generic Pharmaceuticals industry include: Volume and price erosion, Gross margin, New launches and first-to-file exclusivities, Manufacturing cost, Customer concentration among wholesalers. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Generic Pharmaceuticals industry?
The Generic Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Generic Pharmaceuticals industry?
The primary risks for Generic Pharmaceuticals companies include: Price erosion, Customer concentration, Quality and inspection issues, Litigation. Investors should assess each company's exposure to these factors and its track record of navigating them.